New developments in the treatment of patients with diabetic foot ulcer;Het diabetisch voetulcus: Nieuwe ontwikkelingen in de behandeling

Nederlands Tijdschrift voor Geneeskunde

Volumn 144, Issue 9, 2000, Pages 409-412

  Bakker, K ^a,b   Schaper, N C ^a  

^a Infection and Immunology   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR;

ANTIMICROBIAL ACTIVITY; ARTICLE; BIOENGINEERING; DIABETES MELLITUS; DIABETIC FOOT; EXTRACELLULAR MATRIX; HUMAN; HYPERBARIC OXYGEN; INFECTION; LEG ISCHEMIA; MECHANICAL STRESS; METABOLIC REGULATION; NETHERLANDS; PATIENT EDUCATION; POLYNEUROPATHY; SHOE; SKIN BLOOD FLOW; SKIN FIBROBLAST; WOUND CARE;

BIOLOGICAL DRESSINGS; DIABETIC FOOT; DIABETIC NEUROPATHIES; EXTRACELLULAR MATRIX PROTEINS; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GROWTH SUBSTANCES; HUMANS; HYPERBARIC OXYGENATION; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 0034716557     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Schaper NC, Kitslaar PJEHM, Nieuwenhuijzen Kruseman AC. Tekortschietende gezondheidszorg voor diabetespatiënten met voet-problemen. Ned Tijdschr Geneeskd 1994;138:548-50.
2. The international consensus on the diabetic foot. In: Apelqvist J, Bakker K, Houtum WH van, Nabuurs-Franssen MH, Schaper NC, editors. Amsterdam: International Working Group on the Diabetic Foot; 1999.
3. Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995;18:64-9.
4. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991;45:319-26.
5. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995;21: 71-81.
6. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:822-7.
7. Steed DL, Ricotta JJ, Prendergast JJ, Kaplan RJ, Webster MW, McGill JB, et al. Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid (RGD) peptide matrix. RGD Study Group. Diabetes Care 1995;18:39-46.
8. Foster AM, Bates M, Doxford M, Edmonds ME. The treatment of indolent neuropathic ulceration of the diabetic foot with Hyaff. Diabet Med 1999;16:894.
9. Mansbridge J. Skin substitutes to enhance wound healing. Expa Opin Invest Drugs 1998;7:803-9.
10. Trent JF, Kirsner RS. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. Int Clin Pract 1998;52:408-13.
11. Pham HT, Rosenblum BI, Lyons TE, Guirini JM, Chrzan JS, Habershaw SM, et al. Evaluation of graftskin (Apligraf); a human skin equivalent for the treatment of diabetic foot ulcers. Diabetes 1999;48(Suppl 1):A18.
12. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19:350-4.
13. Naughton G, Mansbridge J, Gentzkow GD. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997;21:1203-10.
14. Bakker DJ. Hyperbaric oxygen therapy. Diabetes Metabolism Res Rev [ter perse].
15. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Oriani G, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care 1996;19:1338-43.
16. 2 species in leukocytes from poorly controlled diabetic patients. Diabetes Care 1992;15: 1050-2.
17. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992;15:256-60.
18. Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997;350:855-9.
19. Mueller MJ, Diamond JE, Sinacore DR, Delitto A, Blair 3d VP, Drury DA, et al. Total contact casting in treatment of diabetic plantar ulcers. Controlled clinical trial. Diabetes Care 1989;12:384-8.
20. Nederlandse Diabetes Federatie (NDF) en Kwaliteitsinstituut voor de Gezondheidszorg CBO. Diabetische voet. In: NDF-CBO. Diabetische retinopathie, diabetische nefropathie, diabetische voet & hart- en vaatziekten bij diabetes mellitus 1998. Utrecht: CBO; 1998.
21. Ballegooie E van, Everdingen JJE van. CBO-richtlijnen over diagnostiek, behandeling en preventie van complicaties bij diabetes mellitus: retinopathie, voetulcera, nefropathie en hart- en vaatziekten. Ned Tijdschr Geneeskd 2000;144:413-8.